CEO, Breiten Associates LLC

    報告題目：False positive, negative, and unexpected Drug Testing Results in the Urine Toxicology Laboratory |
    藥物測試：尿液毒理學實驗室使用篩選法（免疫測定法）和確認法（MS）


    報告摘要

In 1995 I co-authored a  short article entitled “False-positive Immunoassay Results for Urine Benzodiazepine in Patients Receiving Oxaprozin (Daypro)”. This was published when rapid urine drug screening test methods were first becoming available. The laboratory community was starting to realize that not all assays can be tested for all of the thousands of drugs, substances or endogenous compounds that may potentially cause result errors. 

There are false positive, false negative and unexpected patient urine drug test results that occur in the Urine Toxicology laboratory. 

How does one research these results and assist the clinician in helping to assess these results to treat their patient?

Unexpected urine drug test results can occur during any phase of the testing process; however, the most common usual results occur  during the pre- analytical or patient collection phase. During this phase patients can provide “fake” urine, take substances that can affect the testing method, or they can adulterate/dilute their urine specimen.

Depending on the screening test method used, the test method can be impacted by a variety of substances that can produce either false negative, false positive or usual results. Screening results can also be different than the confirmation results making interpretation of patient results even more confusing.

During this presentation we will review a basic screening test method and confirmation method. And discuss some of these unexpected urine drug test results. 

     個人簡介

Paul Breitenbecher在羅得島大學、康涅狄格大學、杜肯大學等高校進修了研究生課程，曾在哈佛先鋒醫學中心、諾華生物醫學研究院、病理實驗室公司（Inform Diagnostics，原名Miraca Life Sciences Inc.）等知名醫學機構和企業的實驗室從事管理工作。現任Breiten Associates LLC公司的首席執行官，為臨床實驗室和CRO領域的科研人員提供采購、咨詢等方面的技術支持。